Sana Biotechnology, Inc. SANA 深 沪
等待开盘 04-01 09:30:00 美东时间
2.88
+0.200
+7.46%
华盛通- 最 高2.91
- 今 开2.79
- 成交量 347.32万股
- 最 低 2.75
- 昨 收 2.68
- 总市值 7.69亿
- 52周最高 6.55
- 市盈率 静 --
- 换手率 1.30%
- 52周最低 1.53
- 委 比 63.38%
- 总股本 2.67亿
- 历史最高 44.60
- 量 比 1.12
- 振 幅 5.97%
- 历史最低 1.26
- 每 手 1
- 风险率 1.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sana Biotechnology Announces 14-Month Follow-Up Results From Investigator-Sponsored, First-In-Human Study Transplanting UP421 Into Patient With Type 1 Diabetes Without Any Immunosuppression
Groundbreaking First-in-Human Study Demonstrates Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression14-Month Follow-up Data Show Hypoimmune (HIP)-Modified Islets are
03-13 21:03
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
财报速睇 | Sana Biotechnology, Inc. 2025财年年度营收0.00亿美元，同比增长0.0%；归母净利润亏损2.44亿美元，同比亏损缩窄8.6%
华盛资讯3月4日讯，Sana Biotechnology, Inc.公布2025财年年度业绩，公司年度营收0.00亿美元，同比增长0.0%，归母净利润亏损2.44亿美元，同比亏损缩窄8.6%。
03-04 07:02
Sana Biotechnology Files Shelf Prospectus For Offering Of Securities; No Terms Disclosed
-SEC Filing
03-04 06:25
Sana Biotechnology Appoints Brian Piper CFO
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Brian Piper as Executive Vice President, Chief Financial
02-17 22:06
Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sana Biotechnology will present at the 44th J.P. Morgan Healthcare Conference on January 14, 2026, at 9:45 a.m. PT. The presentation, featuring Steve Harr, CEO, will provide a business overview and updates. The webcast and replay will be available on Sana's Investor Relations page for 30 days post-conference.
01-07 21:26
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
B of A Securities Maintains Buy on Sana Biotechnology, Raises Price Target to $7
B of A Securities maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and raises the price target from $6 to $7.
01-07 01:15
美股周涨跌榜 | 特朗普媒体科技集团周涨51.1%，拟并购TAE转型聚变能源公司；Medline周涨43.6%
DJT周涨51.1%，拟并购TAE转型聚变能源公司；Medline周涨43.6%，本周首挂上市，为年内全球最大规模IPO；爱美医疗周涨34.4%，获拜玛林制药48亿美元收购>>
2025-12-20 09:40
Sana Biotechnology Says Nature Biotechnology Publishes Journal Article Titled "In Vivo Gene Editing Of Human Hematopoietic Stem And Progenitor Cells Using Envelope-Engineered Virus-Like Particles"
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology Broadens Application of Fusogen
2025-12-08 22:05
